- Type / Class
- Equity / COM
- Shares outstanding
- 258,506,508
- Total 13F shares
- 98,221,986
- Share change
- -14,749,545
- Total reported value
- $96,659,560
- Put/Call ratio
- 432%
- Price per share
- $0.98
- Number of holders
- 161
- Value change
- -$21,194,525
- Number of buys
- 72
- Number of sells
- 73
Quarterly Holders Quick Answers
What is CUSIP 29664W105?
CUSIP 29664W105 identifies ESPR - Esperion Therapeutics, Inc. - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29664W105:
Top shareholders of ESPR - Esperion Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
|
Company |
5.6%
|
14,493,020
|
$20,869,948 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.4%
|
11,487,729
|
$16,542,329 | — | 31 Mar 2025 | |
| WASATCH ADVISORS LP |
13F
|
Company |
4.2%
|
10,931,257
|
$15,741,010 | — | 31 Mar 2025 | |
| Bellevue Group AG |
13F
|
Company |
3.8%
|
9,694,064
|
$13,959,452 | — | 31 Mar 2025 | |
| PenderFund Capital Management Ltd. |
13F
|
Company |
0.77%
|
2,000,000
|
$10,786,051 | — | 31 Mar 2025 | |
| Two Seas Capital LP |
13F
|
Company |
2.7%
|
6,930,871
|
$9,980,454 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.5%
|
6,586,632
|
$9,484,752 | — | 31 Mar 2025 | |
| BB BIOTECH AG |
13D/G
|
— |
4.9%
|
9,694,064
|
$8,821,598 | -$227,500 | 04 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
4,548,248
|
$6,549,477 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
4,446,297
|
$6,403,916 | — | 31 Mar 2025 | |
| BIOTECH TARGET N V |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,477,964
|
$5,575,065 | — | 24 May 2021 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.4%
|
3,632,958
|
$5,231,459 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
1.2%
|
3,087,700
|
$4,446,288 | — | 31 Mar 2025 | |
| Indaba Capital Management, L.P. |
13F
|
Company |
1.2%
|
3,000,000
|
$4,320,000 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.1%
|
2,731,287
|
$3,933,053 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.98%
|
2,527,000
|
$3,638,880 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.81%
|
2,091,105
|
$3,011,191 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.74%
|
1,921,707
|
$2,767,258 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.6%
|
1,539,008
|
$2,216,171 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.59%
|
1,527,286
|
$2,199,291 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.59%
|
1,527,263
|
$2,199,259 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.58%
|
1,503,754
|
$2,165,406 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.47%
|
1,217,541
|
$1,753,259 | — | 31 Mar 2025 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.41%
|
1,066,495
|
$1,535,753 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.37%
|
961,035
|
$1,383,890 | — | 31 Mar 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.34%
|
877,408
|
$1,263,468 | — | 31 Mar 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.32%
|
822,618
|
$1,184,570 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.3%
|
762,633
|
$1,098,192 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.29%
|
761,980
|
$1,097,251 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.26%
|
669,918
|
$964,682 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.26%
|
669,829
|
$964,000 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.21%
|
554,216
|
$798,071 | — | 31 Mar 2025 | |
| Joanne M. Foody |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
472,862
mixed-class rows
|
$709,168 | — | 17 Jul 2024 | |
| Graham Capital Management, L.P. |
13F
|
Company |
0.19%
|
487,735
|
$702,338 | — | 31 Mar 2025 | |
| Diametric Capital, LP |
13F
|
Company |
0.17%
|
430,176
|
$619,453 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.16%
|
415,141
|
$597,804 | — | 31 Mar 2025 | |
| Marex Group plc |
13F
|
Company |
0.14%
|
350,000
|
$504,000 | — | 31 Mar 2025 | |
| Summit Wealth Group, LLC |
13F
|
Company |
0.11%
|
293,000
|
$422,000 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.11%
|
275,707
|
$397,018 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.11%
|
271,611
|
$391,120 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.1%
|
255,480
|
$367,891 | — | 31 Mar 2025 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.1%
|
254,265
|
$366,142 | — | 31 Mar 2025 | |
| Eric Warren |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
561,218
mixed-class rows
|
$362,073 | — | 17 Apr 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.09%
|
236,133
|
$340,032 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.09%
|
236,030
|
$339,874 | — | 31 Mar 2025 | |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP |
13F
|
Company |
0.09%
|
222,482
|
$320,374 | — | 31 Mar 2025 | |
| NJ State Employees Deferred Compensation Plan |
13F
|
Company |
0.08%
|
195,125
|
$280,980 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.07%
|
186,645
|
$268,769 | — | 31 Mar 2025 | |
| Pentwater Capital Management LP |
13F
|
Company |
0.07%
|
181,290
|
$261,058 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.07%
|
180,227
|
$259,527 | — | 31 Mar 2025 |
Institutional Holders of Esperion Therapeutics, Inc. - COM (ESPR) as of Q2 2025
As of 30 Jun 2025,
Esperion Therapeutics, Inc. - COM (ESPR) was held by
161 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
98,221,986 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, WASATCH ADVISORS LP, Two Seas Capital LP, PenderFund Capital Management Ltd., MARSHALL WACE, LLP, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, Indaba Capital Management, L.P., and CITADEL ADVISORS LLC.
This page lists
160
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
183
Q2 2025 holders
161
Holder diff
-22
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.